Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low molecular weight heparins: a developmental perspective.

J Fareed1, D Hoppensteadt, W Jeske

  • 1Dept. of Pathology and Pharmacology, Loyola University Medical Center, 2160 S. First Ave., Maywood, IL 60153, USA. JFareed@LUC.edu

Expert Opinion on Investigational Drugs
|June 1, 1997
PubMed
Summary

Low molecular weight heparins (LMWHs) show distinct antithrombotic effects and tissue factor pathway inhibitor (TFPI) release, varying by product. Manufacturing differences lead to unique pharmacological profiles, impacting clinical use and substitution.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional and Systemic Prothrombotic Biomarkers in Varicose Vein Patients and Healthy Controls.

Journal of vascular surgery. Venous and lymphatic disorders·2016
Same author

Blood Sampled Directly from Varicose Veins Reveals Activation of Inflammatory Processes.

Journal of vascular surgery. Venous and lymphatic disorders·2016
Same author

Do blood constituents in varicose veins differ from the systemic blood constituents?

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2015
Same author

Elevated endocan levels and its association with clinical severity in Stevens-Johnson Syndrome and toxic epidermal necrolysis.

International angiology : a journal of the International Union of Angiology·2014
Same author

Pharmacological profile of sulodexide.

International angiology : a journal of the International Union of Angiology·2014
Same author

Medical management of patients with peripheral arterial disease.

International angiology : a journal of the International Union of Angiology·2014

Area of Science:

  • Pharmacology
  • Biochemistry
  • Thrombosis Research

Background:

  • Low molecular weight heparins (LMWHs) are standard for preventing deep vein thrombosis (DVT) post-surgery.
  • LMWHs are also explored for treating thrombosis and cardiovascular conditions.
  • Manufacturing variations create distinct pharmacological and biochemical profiles for each LMWH product.

Purpose of the Study:

  • To compare the antithrombotic and hemorrhagic effects of different LMWH products.
  • To investigate the role of tissue factor pathway inhibitor (TFPI) release in LMWH actions.
  • To highlight product individuality and the limitations of standardization in predicting clinical effects.

Main Methods:

  • Evaluation of dose- and time-dependent antithrombotic effects in animal models.

Related Experiment Videos

  • Assessment of ex vivo anticoagulant actions and sustained antithrombotic effects.
  • Measurement of TFPI release following intravenous (iv.) and subcutaneous (sc.) administration in animal and primate models.
  • Analysis of repeated administration effects on antithrombotic and hemorrhagic responses.

    • Main Results:

    • LMWHs exhibit product-specific antithrombotic effects and TFPI release.
    • Sustained antithrombotic effects can occur without detectable ex vivo anticoagulant activity.
    • Repeated LMWH administration enhances antithrombotic effects, with variable hemorrhagic responses dependent on the product.
    • TFPI release demonstrates product individuality and relevance to LMWH actions.

    Conclusions:

    • Product individuality is a key factor in LMWH efficacy and safety.
    • Standardization protocols are insufficient for product substitution or predicting clinical outcomes.
    • Understanding distinct LMWH profiles is crucial for optimizing thrombosis treatment and prophylaxis.